دورية أكاديمية
Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.
| العنوان: | Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. |
|---|---|
| المؤلفون: | Vitolins MZ; Mara Z. Vitolins, Leah Griffin, Bart Frizzel, Glenn J. Lesser, Michelle Naughton, and Edward G. Shaw, Wake Forest School of Medicine; Dawn Moose, Novant Health, Winston-Salem; James E. Radford Jr, Hendersonville Hematology/Oncology, Hendersonville, NC; W. Vic Tomlinson, AnMed Health, Anderson, SC; Jacqueline Vuky, Virginia Mason Medical Center, Seattle, WA; and Paul T. Adams, National Surgical Adjuvant Breast and Bowel Project, Genesys Regional Medical Center, Flint, MI., Griffin L, Tomlinson WV, Vuky J, Adams PT, Moose D, Frizzell B, Lesser GJ, Naughton M, Radford JE Jr, Shaw EG |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2013 Nov 10; Vol. 31 (32), pp. 4092-8. Date of Electronic Publication: 2013 Sep 30. |
| نوع المنشور: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology Original Publication: New York, N.Y. : Grune & Stratton, c1983- |
| مواضيع طبية MeSH: | Androgen Antagonists/*adverse effects , Cyclohexanols/*therapeutic use , Hot Flashes/*prevention & control , Prostatic Neoplasms/*drug therapy , Selective Serotonin Reuptake Inhibitors/*therapeutic use , Soybean Proteins/*therapeutic use, Aged ; Aged, 80 and over ; Double-Blind Method ; Hot Flashes/etiology ; Humans ; Male ; Middle Aged ; Quality of Life ; Venlafaxine Hydrochloride |
| مستخلص: | Purpose: Hot flashes occur in approximately 80% of androgen-deprived men. Few intervention studies have been conducted to relieve hot flashes in men. Patients and Methods: Eligible androgen-deprived men were randomly assigned to one of four daily regimens (2 × 2 factorial design) for 12 weeks: milk protein powder and placebo pill, venlafaxine and milk protein powder, soy protein powder and placebo pill, or venlafaxine and soy protein powder. The primary end point was hot flash symptom severity score (HFSSS), defined as number of hot flashes times severity. The secondary end point was quality of life (QoL), assessed by using the Functional Assessment of Cancer Therapy-Prostate. Results: In all, 120 men age 46 to 91 years participated. Most were white (78%) and overweight or obese (83%). Toxicity was minimal. Neither venlafaxine nor soy protein alone or in combination had a significant effect on HFSSS. Soy protein, but not venlafaxine, improved measures of QoL. Conclusion: In androgen-deprived men, neither venlafaxine nor soy proved effective in reducing hot flashes. Interventions that appear effective for decreasing hot flashes in women may not always turn out to be effective in men. |
| References: | Lancet Oncol. 2010 Feb;11(2):147-54. (PMID: 19963436) Menopause. 2010 May-Jun;17(3):660-6. (PMID: 20464785) Urology. 1997 Dec;50(6):920-8. (PMID: 9426724) Neurosci Res. 2008 Feb;60(2):156-61. (PMID: 18054104) Breast Cancer Res Treat. 2009 Jun;115(3):573-80. (PMID: 18670875) Cochrane Database Syst Rev. 2007 Oct 17;(4):CD001395. (PMID: 17943751) Menopause. 2003 Mar-Apr;10(2):147-53. (PMID: 12627040) J Clin Oncol. 1993 Mar;11(3):570-9. (PMID: 8445433) J Clin Oncol. 2002 Mar 15;20(6):1449-55. (PMID: 11896091) Am J Clin Nutr. 1998 Dec;68(6 Suppl):1333S-1346S. (PMID: 9848496) J Urol. 2009 Nov;182(5):2265-72. (PMID: 19758646) Obstet Gynecol. 1998 Jan;91(1):6-11. (PMID: 9464712) Lancet. 2000 Dec 16;356(9247):2059-63. (PMID: 11145492) Urol Nurs. 1994 Dec;14(4):155-8. (PMID: 7817208) Psychooncology. 1998 Mar-Apr;7(2):129-32. (PMID: 9589512) J Med Food. 2003 Spring;6(1):1-11. (PMID: 12804015) Obstet Gynecol. 1996 May;87(5 Pt 2):897-904. (PMID: 8677131) Urology. 1989 Mar;33(3):175-8. (PMID: 2465644) Maturitas. 1995 Apr;21(3):189-95. (PMID: 7616867) South Med J. 1998 Sep;91(9):855-7. (PMID: 9743058) J Urol. 1999 Jul;162(1):98-102. (PMID: 10379749) Mayo Clin Proc. 2002 Nov;77(11):1207-18. (PMID: 12440557) |
| معلومات مُعتمدة: | P30 CA012197 United States CA NCI NIH HHS; U10 CA081851 United States CA NCI NIH HHS; U10 CA081851-06S2 United States CA NCI NIH HHS; U10 CA 081851-06S2 United States CA NCI NIH HHS |
| سلسلة جزيئية: | ClinicalTrials.gov NCT00354432 |
| المشرفين على المادة: | 0 (Androgen Antagonists) 0 (Cyclohexanols) 0 (Serotonin Uptake Inhibitors) 0 (Soybean Proteins) 7D7RX5A8MO (Venlafaxine Hydrochloride) |
| تواريخ الأحداث: | Date Created: 20131002 Date Completed: 20140107 Latest Revision: 20221207 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC3816959 |
| DOI: | 10.1200/JCO.2012.48.1432 |
| PMID: | 24081940 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!